OBJECTIVE: To elaborate recommendations for the treatment of rheumatoid arthritis in Brazil. METHOD: Literature review with articles' selection based on evidence and the expert opinion of the Rheumatoid Arthritis Committee of the Brazilian Society of Rheumatology. RESULTS AND CONCLUSIONS: 1) The therapeutic decision should be shared with the patient; 2) immediately after the diagnosis, a disease-modifying antirheumatic drug (DMARD) should be prescribed, and the treatment adjusted to achieve remission; 3) treatment should be conducted by a rheumatologist; 4) the initial treatment includes synthetic DMARDs; 5) methotrexate is the drug of choice; 6) patients who fail to respond after two schedules of synthetic DMARDs should be assessed for the use of biologic DMARDs; 7) exceptionally, biologic DMARDs can be considered earlier; 8) anti-TNF agents are preferentially recommended as the initial biologic therapy; 9) after therapeutic failure of a first biologic DMARD, other biologics can be used; 10) cyclophosphamide and azathioprine can be used in severe extra-articular manifestations; 11) oral corticoid is recommended at low doses and for short periods of time; 12) non-steroidal anti-inflammatory drugs should always be prescribed in association with a DMARD; 13) clinical assessments should be performed on a monthly basis at the beginning of treatment; 14) physical therapy, rehabilitation, and occupational therapy are indicated; 15) surgical treatment is recommended to correct sequelae; 16) alternative therapy does not replace traditional therapy; 17) family planning is recommended; 18) the active search and management of comorbidities are recommended; 19) the patient's vaccination status should be recorded and updated; 20) endemic-epidemic transmissible diseases should be investigated and treated.
OBJECTIVE: To elaborate recommendations for the treatment of rheumatoid arthritis in Brazil. METHOD: Literature review with articles' selection based on evidence and the expert opinion of the Rheumatoid Arthritis Committee of the Brazilian Society of Rheumatology. RESULTS AND CONCLUSIONS: 1) The therapeutic decision should be shared with the patient; 2) immediately after the diagnosis, a disease-modifying antirheumatic drug (DMARD) should be prescribed, and the treatment adjusted to achieve remission; 3) treatment should be conducted by a rheumatologist; 4) the initial treatment includes synthetic DMARDs; 5) methotrexate is the drug of choice; 6) patients who fail to respond after two schedules of synthetic DMARDs should be assessed for the use of biologic DMARDs; 7) exceptionally, biologic DMARDs can be considered earlier; 8) anti-TNF agents are preferentially recommended as the initial biologic therapy; 9) after therapeutic failure of a first biologic DMARD, other biologics can be used; 10) cyclophosphamide and azathioprine can be used in severe extra-articular manifestations; 11) oral corticoid is recommended at low doses and for short periods of time; 12) non-steroidal anti-inflammatory drugs should always be prescribed in association with a DMARD; 13) clinical assessments should be performed on a monthly basis at the beginning of treatment; 14) physical therapy, rehabilitation, and occupational therapy are indicated; 15) surgical treatment is recommended to correct sequelae; 16) alternative therapy does not replace traditional therapy; 17) family planning is recommended; 18) the active search and management of comorbidities are recommended; 19) the patient's vaccination status should be recorded and updated; 20) endemic-epidemic transmissible diseases should be investigated and treated.
Authors: Bárbara P Fafá; Paulo Louzada-Junior; David C Titton; Eliana Zandonade; Roberto Ranza; Ieda Laurindo; Paula Peçanha; Aline Ranzolin; André L Hayata; Angela Duarte; Inês G Silveira; Izaias Costa; José C Macieira; Luiz S Guedes-Barbosa; Manoel B Bertolo; Maria Fátima Lobato da C Sauma; Marília B G Silva; Marlene Freire; Morton A Scheinberg; Vander Fernandes; Washington Bianchi; José R S Miranda; Geraldo R C Pinheiro; Hellen M S Carvalho; Claiton Viegas Brenol; Ivanio A Pereira; Gláucio Ricardo Werner de Castro; Júlio C Bertacini de Morais; Sheila K F Oliveira; Mirhelen Mendes de Abreu; Roberto A Toledo; Marcelo M Pinheiro; Walber Pinto Vieira; Valéria Valim Journal: Clin Rheumatol Date: 2015-04-08 Impact factor: 2.980
Authors: Amanda Bezerra Gonçalves; Júlia Leme Bovo; Bruna Silva Gomes; Acácio Antonio Pigoso; Maíra Felonato; Marcelo Augusto Marretto Esquisatto; Gaspar de Jesus Lopes Filho; Fernando Russo Costa do Bomfim Journal: J Lasers Med Sci Date: 2021-10-18
Authors: Jéssica Barreto Ribeiro Dos Santos; Alessandra Maciel Almeida; Francisco de Assis Acurcio; Haliton Alves de Oliveira Junior; Adriana Maria Kakehasi; Augusto Afonso Guerra Junior; Marion Bennie; Brian Godman; Juliana Alvares Journal: J Comp Eff Res Date: 2016-09-19 Impact factor: 1.744
Authors: Carina Mori Frade Gomes; Maria Teresa Terreri; Maria Isabel de Moraes-Pinto; Cássia Barbosa; Natália Pereira Machado; Maria Roberta Melo; Marcelo Medeiros Pinheiro Journal: Mem Inst Oswaldo Cruz Date: 2015-11 Impact factor: 2.743